DiaMedica Therapeutics Inc. Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture
DiaMedica Therapeutics Inc. (DMAC) reported Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture of $1.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement
us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation · last filed 2026-08-10
- DiaMedica Therapeutics Inc. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2026-06-30 was $1.12M, a 45.01% increase year-over-year.
- DiaMedica Therapeutics Inc. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2026-03-31 was $822.00K, a 5.19% decline year-over-year.
- DiaMedica Therapeutics Inc. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-09-30 was $1.02M, a 79.82% increase year-over-year.
- DiaMedica Therapeutics Inc. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-06-30 was $771.00K, a 74.04% increase year-over-year.
- DiaMedica Therapeutics Inc. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2025 was $3.85M, a 84.46% increase from fiscal 2024.
- DiaMedica Therapeutics Inc. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2024 was $2.08M, a 23.89% increase from fiscal 2023.
- DiaMedica Therapeutics Inc. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2023 was $1.68M, a 12.05% increase from fiscal 2022.
- DiaMedica Therapeutics Inc. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2022 was $1.50M, a 3.59% decline from fiscal 2021.
| Period end | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 6 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 9 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.12M 10-Q · filed 2026-08-10 | $1.94M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $822.00K 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $3.85M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $1.02M 10-Q · filed 2025-11-12 | $1.79M derived: sum of 2 quarters · filed 2026-08-10 | $2.65M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | $771.00K 10-Q · filed 2026-08-10 | $1.64M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $867.00K 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $2.08M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $565.00K 10-Q · filed 2025-11-12 | $1.01M derived: sum of 2 quarters · filed 2025-11-12 | $1.50M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $443.00K 10-Q · filed 2025-11-12 | $931.00K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $488.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $1.68M 10-K · filed 2025-03-17 | |||
| 2023-09-30 | $425.00K 10-Q · filed 2024-11-13 | $805.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.23M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $380.00K 10-Q · filed 2024-11-13 | $802.00K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $422.00K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $1.50M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $418.00K 10-Q · filed 2023-11-13 | $783.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.09M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $365.00K 10-Q · filed 2023-11-13 | $673.00K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $308.00K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $1.56M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $303.00K 10-Q · filed 2022-11-09 | $749.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.26M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $446.00K 10-Q · filed 2022-11-09 | $957.00K derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $511.00K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $1.84M 10-K · filed 2022-03-14 | |||
| 2020-09-30 | $508.00K 10-Q · filed 2020-11-04 | $944.00K derived: sum of 2 quarters · filed 2021-08-11 | $1.34M derived: sum of 3 quarters · filed 2021-08-11 | |
| 2020-06-30 | $436.00K 10-Q · filed 2021-08-11 | $829.00K 10-Q · filed 2020-08-11 | ||
| 2020-03-31 | $393.00K 10-Q · filed 2021-08-11 | |||
| 2019-12-31 | $1.16M 10-K · filed 2021-03-10 | |||
| 2019-09-30 | $451.00K 10-Q · filed 2020-11-04 | $633.00K derived: sum of 2 quarters · filed 2020-11-04 | $763.00K derived: sum of 3 quarters · filed 2020-11-04 | |
| 2019-06-30 | $182.00K 10-Q · filed 2020-11-04 | $312.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $130.00K 10-Q · filed 2020-11-04 | |||
| 2018-12-31 | $620.00K 10-K · filed 2020-03-23 | |||
| 2017-12-31 | $409.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |